Given that biallelic loss of CDK12 represents an immunogenic molecular subtype of prostate cancer and the crucial role of T cells in antitumor immunity, we speculated that CDK12/13 could represent a therapeutic avenue for triggering antitumor immune responses and thereby enhance ICB efficacy. The gene discussed is CDK12; the disease is prostate carcinoma.